Title and Contents Page 1

Education and Training Page 2

Certification and Licensure Page 2

Academic, Administrative, and Clinical Appointments Page 2

Research Interests Page 3

Grants Page 3

Honors and Awards Page 5

Memberships in Professional Societies Page 5

Editorial Positions, Boards, and Peer-Review Service Page 5

Teaching Page 7

Committee, Organizational, and Volunteer Service Page 11

Consulting Positions Page 12

Visiting Professorships, Seminars, and Extramural Invited Presentations Page 12

Patents Page 15

Bibliography Page 15

Theodore J. Standiford, M.D.

Professor of Medicine

Division of Pulmonary & Critical Care Medicine

109 Zina Pitcher Place

4062 Biomedical Sciences Research Building

Ann Arbor, MI 48109-2200

Phone: 734-764-4554

FAX: 734-615-2331

Email: tstandif@umich.edu

**Education and Training**

Education:

9/1972 – 6/1976 John Glenn High School, Bay City, MI

9/1976 – 6/1980 Alma College, Alma, MI, B.S.

9/1980 – 6/1984 Wayne State University, Detroit, MI, M.D.

Training:

7/1/84 – 6/30/85 Internship, University of Minnesota Hospitals, Minneapolis, MN

7/1/85 – 6/30/88 Resident, University of Minnesota Hospitals, Minneapolis, MN

7/1/86 – 6/30/88 Chief Medical Resident, VA Medical Center, University of Minnesota Hospitals, Minneapolis, MN

7/1/88 – 6/30/91 Pulmonary Fellow, Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

**Certification and Licensure**

1/1/87 – 12/31/88 Medical Licensure, Minnesota

1/1/88- Medical Licensure, Michigan #4301053979

9/16/87 Board Certification, Internal Medicine #114912

11/5/91-12/31/2021 Board Certification, Pulmonary Medicine #114912

11/5/91-12/31/2011 Board Certification, Critical Care Medicine #114912

**Academic, Administrative and Clinical Appointments**

Academic Appointments:

7/1/90 – 6/30/91 Lecturer, Division of Pulmonary & Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

7/1/91 – 6/30/96 Assistant Professor, Division of Pulmonary & Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

7/1/96 – 6/30/00 Associate Professor with tenure, Division of Pulmonary & Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

7/1/00-present Professor, Division of Pulmonary & Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI.

Administrative Appointments:

9/15/00-present Program Director, T32 Multidisciplinary Training Program in Lung Diseases

9/19/11-present Interim Chief, Division of Pulmonary & Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

Clinical Appointments:

7/1/87-6/30/88 Staff Physician, Pulmonary Service, Veterans Administration Hospital/University of Minnesota, Minneapolis, MN

7/1/87-present Staff Physician, Pulmonary Service, Veterans Administration Hospital/University of Michigan Medical Center, Ann Arbor, MI

7/1/96-6/30/06 Medical Director, 6C, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, MI

6/2012-present TB Consultant, Washtenaw County Health Department

**Research Interests**

1. Basic mechanisms of lung innate host defense
2. Regulation of inflammatory responses in sepsis and sepsis-induced lung injury
3. Toll-like receptors
4. Molecular regulation of tumor cell growth/apoptosis in non-small cell lung cancer
5. Clinical trials in sepsis and ARDS

**Grants**

##### Present and Active:

NIH/NHLBI, R01 HL097564

Flagellin Stimulates Lung Innate Mucosal Immunity

PI: T. Standiford (25% effort)

04/01/10 – 03/31/14 ($314,680 annual direct costs)

Role: Principal Investigator

NIH/NHLBI, T32 HL007749

Multidisciplinary Training Program in Lung Disease

PD: T. Standiford (10% effort)

07/01/93 – 06/30/13 ($730,364 annual directs)

Role: Program Director

NIH/NHLBI, R01 AI065543

PGE2 Regulation of Host Defense Post-Bone Marrow Transplant (BMT)

PI: B. Moore, Co-I: T. Standiford (5% effort)

05/15/07 – 04/30/12 ($250,000 annual direct costs)

Role: Co-Investigator

NIH/NHLBI, 2 R01 HL31237

Monokine Gene Expression/Regulation in Lung Injury

PI: S. Kunkel, Co-I: T. Standiford (5% effort)

01/01/09 – 12/31/13 (250,000 annual direct costs)

Role: Co-Investigator

 NIH/NHLBI, RFA CA-07-046

 Regulation of Tumor Associated Macrophages by TGF-beta

 PI: V. Keshamouni, Co-I: T. Standiford (5% effort)

 05/05/08 – 04/30/13

 Role: Co-Investigator

Pending Grants:

NIH/NHLBI, RFP HR-14-03

NHLBI Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury Clinical Center (PETAL)

Co-PIs: R. Hyzy, T. Standiford (5% effort)

07/1/13 – 06/30/2020 ($197,608 annual direct costs)

Role: Co-Principal Investigator

Previous Grants:

NIH/NHLBI, 2 R01 HL25243

Role of TLR9 in Lung Antibacterial Host Defense

PI: T. Standiford (30% effort)

04/01/07 – 03/31/12 ($250,000 annual direct costs)

Role: Principal Investigator

NIH/NHLBI, 5 P50 HL074024

SCCOR in Translational Research in Acute Lung Injury

Project 3: Macrophage Activation/Deactivation in ALI

PD/PI: T. Standiford (20% effort)

09/01/03 – 06/30/09 ($230,618 annual direct costs, no cost extension)

Role: Principal Investigator

NIH/NHLBI, 5 P50 HL074024

SCCOR in Translational Research in Acute Lung Injury

Core B: Administrative Core

PD/PI: T. Standiford (5% effort)

09/01/03-06/30/09 ($131,876 annual direct costs, no cost extension)

Role: Principal Investigator

FA7014-07-C-A010

Department of Defense, Airforce

PI: L. Napolitano, Co-I: T. Standiford (5% effort)

09/28/07 – 06/30/09 (335, 733 annual direct costs)

Role: Co-Investigator

NIH/NHLBI, U10 HL074422

Strategies to Prevent Chronic Obstructive Pulmonary Disease (COPD) Exacerbation (COPD Clinical Research Network)

PI: F. Martinez, Co-I: T. Standiford (5% effort)

09/28/04 – 07/31/09 ($294,688 annual direct costs)

Role: Co-Investigator

Centocor Research & Development, Inc.

TLR3 in the Lung of ALI/ARDS

PI: T. Standiford (3% effort)

11/16/06 – 06/30/10 ($52,428 annual direct costs)
Role: Principal Investigator

**Honors and Awards**

1984 Alpha Omega Alpha

1992 Edward Livingston Trudeau Scholar of the American Lung Association

1995 Jerome W. Conn Excellence in Biomedical Research Award, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

1998 Special Recognition for Contributions to the House Officer Teaching Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

2003 American Society for Clinical Investigation (ASCI)

2009 Association of American Physicans (AAP)

**Memberships in Professional Societies**

1988- American Thoracic Society

1992-1998 American Federation of Medical Research

1992- American Association of Immunologists

1993-2000 Central Society of Clinical Research

1997- American Society of Microbiology

2003- American Society for Clinical Investigation

2009- Association of American Physicians

**Editorial Positions, Boards and Peer-Review Service**

Reviewer:

1991- *American Journal of Respiratory Cell and Molecular Biology*

1991- *Journal of Laboratory and Clinical Medicine*

1992- *Journal of Immunology*

1992- *American Review of Respiratory Diseases*

1992- *Chest*

1992- *Journal of Infectious Disease*

1993- *American Journal of Pathology*

1993- *Journal of Leukocyte Biology*

1994- *Infection and Immunity*

1994- *American Journal of Physiology*

1994- *Blood*

1995- *Journal of Investigative Medicine*

1996- *European Respiratory Journal*

1996- *Journal of Clinical Investigation*

1998- *Journal of Applied Physiology*

1998- *Alcoholism: Clinical and Experimental Research*

2005- *Immunity*

2007- *Nature Medicine*

2009- *Mucosal Immunity*

2010- *Journal of Innate Immunity*

2011- *PLoS One*

2013 *PLoS Pathogens*

Editorial Boards:

1995-1998 Associate Editor, *Journal of Immunology*

1998-2002 Section Editor, *Journal of Immunology*

1998-present Editorial Board, *American Journal of Respiratory Cell and Molecular Biology*

2006-present Associate Editor, *Journal of PPAR Research*

2007-2010 Associate Editor, *American Journal of Respiratory and Critical Care Medicine*

2011-present Editorial Board, *World Journal of Critical Infectious Diseases*

Study Sections:

09/94 Ad Hoc Reviewer, Merit Review Board for Respiration, Veterans Administration

03/27-03/29/95 Member, Special Review Committee, RFA-NIH-AI-94-21, Asthma, Allergic and Immunologic Diseases Cooperative Center, National Institute of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD

07/22-07/23/97 Ad Hoc Reviewer, Physiology Study Section, National Institute of Health, Bethesda, MD

01/25-01/26/98 Ad Hoc Reviewer, Research Grant Review Committee, American Lung Association, New York, NY

03/26-03/27/98 External Reviewer, “Bacterial Respiratory Tract Infections: Pathogenesis and Prevention,” State University of New York, Buffalo, NY

10/30/98 Ad Hoc Reviewer, Small Business Applications, National Institute of Health, NHLBI, Bethesda, MD

2/24-2/25/99 Ad Hoc Reviewer, Lung Biology and Pathology Study Section, National Institute of Health, Bethesda, MD

05/21/99 Ad Hoc Reviewer, Program Project Grant Review, National Institute of Health, Bethesda, MD

10/25/99 Ad Hoc Reviewer, Clinical Trials Review Committee, National Institute of Health, Bethesda, MD

7/1/00-10/7/03 Member, Lung Biology and Pathology Study Section, National Institute of Health, Bethesda, MD

2/25/04-6/30/04 Member, Lung Cellular and Molecular Immunology Study Section, National Institute of Health, Bethesda, MD.

01/03-01/08 Member, American Lung Association Career Investigator and Research Fellowship Grant Review Committee, New York, NY.

03/04-11/08 Chair, American Lung Association Career Investigator and Research Fellowship Grant Review Committee, New York, NY.

05/07-05/13 Member, Loan Repayment Program (L30) Review Committee National Institiutes of Health, Bethesda, MD

12/17/07 Reviewer, NIAID P01, Special Review Committee Teleconference

10/08-6/12 Member, Lung Cellular and Molecular Immunology Study Section, National Institutes of Health, Bethesda, MD

6/25/13 Reviewer, NHLBI T32 Special Emphasis Panel

**Teaching**

**Postdoctoral Research Trainees**

1992-1994 Glenn M. Van Otteren, M.D., Private Practice of Pulmonary Medicine

1994-1996 Marc Greenberger, M.D., Private Practice of Pulmonary Medicine

1996-1998 David Zisman, M.D., Assistant Professor, Division of Pulmonary and Critical Care Medicine, UCLA Medical Center

1996-present Wan Tsai, M.D., Assistant Professor, Department of Pediatrics, University of Michigan

1997-present Thomas Moore, Ph.D., Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of Michigan

1998-2001 Borna Mehrad, M.D., Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern

1999-2001 Gina Chen, M.D., Private Practice of Pulmonary Medicine

1999-present Raju Reddy, M.D., Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of Michigan

2000-2005 Jane Deng, M.D., Assistant Professor, Division of Pulmonary and Critical Care Medicine, UCLA Medical Center

2001-2002 Ian Smith, M.D., Medical Resident, University of Michigan

2002-2005 Venkateshwar Keshamouni, Ph.D., Research Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of Michigan

2003 Mehrdad Ghaffari, M.D., Medical Resident

2005-present Urvashi Bhan, M.D., Research Fellow, Division of Pulmonary and Critical Care Medicine, University of Michigan

2005-2008 Monica Smith, Ph.D., Postdoctoral Fellow, Division of Pulmonary and Critical Care Medicine, University of Michigan

2006-2009 Kenneth Lyn-Kew, M.D., Research Fellow, Division of Pulmonary and Critical Care Medicine, University of Michigan

2007-2008 Seth Hartung, Medical Resident, University of Michigan

2007-2008 Eric Rich, Medical Resident, University of Michigan

2009-present Megan Ballinger, Ph.D., Postdoctoral Research Fellow

2009-present Melissa Kovach, M.D., Postdoctoral Research Fellow

2011-present Leslie Tolle, M.D., Postdoctoral Research Fellow

**Undergraduate Research Trainees**

1994-1997 Lauri L. Laichalk, College of Literature, Arts & Science, University of Michigan

1998 Sandya Krishnan, College of Literature, Arts & Science, University of Michigan

2001 Tiffany Smith, Grand Valley State University

2007-2008 Matthew Cornicelli, Notre Dame University

2007-2008 Ryan Booth, College of Literature, Arts & Science, University of Michigan

2011-present Jacqueline Neagos, College of Literature, Arts & Science, University of Michigan.

**Visiting Scholars**

2001-2003 Kazuhiro Tateda, M.D., Ph.D., Associate Professor, Toho University, Tokyo, Japan

2008-2009 Masafumi Seki, M.D., Ph.D., Associate Professor, Nagasaki University, Nagasaki, Japan

**Graduate Student Preliminary Committee**

2007 Adam Booth

2007 Penghui Yu

2008 Hemanth Ramaprakash

**Graduate Student Thesis Committee**

2003-2005 Mairi Noverr

2008-2011 Hemanth Ramaprakash

**Postgraduate Fellow Scientific Advisory Committee**

2002-2005 Michal Olszewski, D.V.M., Ph.D.

2004-2007 Jamie Milan, Ph.D.

2005-2008 Monica Smith, Ph.D.

2005-2008 Tracy McMillan, M.D.

2006-2010 Christine Freeman, Ph.D.

2007-2010 Rommel Sagana, M.D.

2010-2013 Payal Naik, M.D.

2011-2013 Adam Booth, Ph.D.

2012-present Stephanis Mathes, Ph.D.

**University of Michigan Teaching**

1990- Attending Physician, Pulmonary Inpatient Service, University of Michigan Hospital, 1 month/year

1991- Attending Physician, Critical Care Medicine Unit, University of Michigan Hospital, 1 month/year

1991- Supervision and teaching of postdoctoral fellows in bronchoscopy and procedures, approximately 12 weeks per year

1991- Supervision and teaching of postdoctoral fellows in Pulmonary Function Testing interpretation, approximately 8 weeks per year

1993- Attending Physician, Pulmonary Consult Service, Ann Arbor Veterans Administration Medical Center, 1 month/year

1993- Chief Rounds and Morning Report, Department of Internal Medicine, University of Michigan Medical School, approximately 12 sessions per year

1995-1996 M2 Physical Diagnosis/Clinical Skills Instructor, University of Michigan Medical School

**University of Michigan Lectures**

08/20/91 Lecturer, Pulmonary Research Conference, "Lung Chemotactic Cytokine Networks," Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

02/03/92 Lecturer, Grand Rounds, "Idiopathic Pulmonary Fibrosis: The Role of Lung Chemotactic Cytokines" Department of Internal Medicine

03/05/92 Lecturer, Pulmonary Research Conference, "Allergic Bronchopulmonary Aspergillosis," Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

08/20/92 Lecturer, Pulmonary Research Conference, "The Role of Macrophage Inflammatory Protein 1 Alpha in Acute and Chronic Pulmonary Inflammation,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

02/17/93 Lecturer, CCU Nursing Inservice, "Pulmonary Fibrosis/Amiodarone Lung Toxicity," Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

08/17/93 Lecturer, Medicine Conference, "Current Concepts in the Diagnosis and

 Management of IPF," Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

12/13/93 Invited Speaker, Clinical Pathological Conference, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

08/06/94 Lecturer, Pulmonary Research Conference, "The Role of Cytokines in Lung Inflammation and Injury,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

05/26/95 Invited Discussant, Clinical Pathological Conference, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

08/26/95 Lecturer, Pulmonary Research Conference, “The Role of Cytokines in Endotoxin-induced Lung Injury,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

11/13/95 Lecturer, Grand Rounds, “Nosocomial Pneumonia in the Post-Antibiotic Era,” Department of Internal Medicine

08/17/96 Lecturer, Pulmonary Research Conference, "The Role of Cytokines in Antibacterial Host Defense,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

10/15/97 Lecturer, Pulmonary Research Conference, "Immunotherapy in gram-negative sepsis and pneumonia,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

07/25/96 Invited Discussant, Clinical Pathological Conference, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

09/16/96 Lecturer, Gene Therapy Seminar, “Interleukin-12 Gene Therapy in Gram-negative Bacterial Pneumonia,” Division of Molecular Medicine and Genetics

11/01/96 Lecturer, Pulmonary Research Conference, "The Role of Cytokines in Lung Antibacterial Host Defense,” Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

1994-1996 M2 Physical Diagnosis/Clinical Skills Instructor, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

1991-1997 Pulmonary Section Physical Diagnosis Instruction, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine

05/29/97 Invited Discussant, CPC, Department of Internal Medicine

06/30/97 Invited Discussant, CPC, Department of Internal Medicine

02/26/98 Invited Discussant, CPC, Department of Internal Medicine

07/29/98 Invited Discussant, CPC, Department of Internal Medicine

09/21/98 Invited Discussant, CPC, Department of Internal Medicine

10/16/98 Invited Discussant, CPC, Department of Internal Medicine

05/19/99 Lecturer, Resident Noon Conference, “Current Concepts in the Diagnosis and Management of Community Acquired Pneumonia,” Department of Internal Medicine

06/14/99 Invited Discussant, CPC, Department of Internal Medicine

08/27/99 Lecturer, Pulmonary Research Conference, “Chemokines as Mediators of Lung Antibacterial Host Defense,” Division of Pulmonary and Critical Care Medicine

12/03/99 Lecturer, Internal Medicine Grand Rounds, “Nosocomial Pneumonia in the 21st Century: Lessons From the Bench,” Department of Internal Medicine

09/15/00 Lecturer, Noon conference, “Nosocomial Pneumonia.” Department of Neurology.

11/14/00 Lecturer, Immunology Graduate Series, “Cytokine-mediated Innate Immunity in Murine *Klebsiella* Pneumonia”, Department of Immunology & Microbiology.

02/09/01 Invited Discussant, CPC, Department of Internal Medicine

06/01/01 Lecturer, Division of Hematology, "Role of Chemokines in Innate Immune Responses of the Lung", Department of Internal Medicine, University of Michigan

11/30/01 Lecturer, Pulmonary Research Conference, "Sepsis-induced Immunosuppression: Role of PPAR-γ", Division of Pulmonary and Critical Care Medicine, University of Michigan

08/30/02 Invited Discussant, CPC, Department of Internal Medicine, University of Michigan

12/16/02 Lecturer, Critical Care Conference, "Nosocomial Pneumonia", Department of Internal Medicine, University of Michigan

10/09/03 Lecturer, Pulmonary Conference, "Evolving Strategies in ARDS", Division of Pulmonary and Critical Care Medicine, University of Michigan

12/04/03 Lecturer, Noon Conference, "Nosocomial Pneumonia", Department of Internal Medicine, University of Michigan

09/27/05 Lecturer, Pulmonary Education Day, “Acute Respiratory Failure I”, 6C Nursing Inservice, University of Michigan Medical Center

11/10/05 Lecturer, Pulmonary Education Day, “Acute Respiratory Failure II”, 6C Nursing Inservice, University of Michigan Medical Center

3/31/06 Invited Discussant, CPC, Department of Internal Medicine, University of Michigan

11/18/06 Invited Discussant, CPC, Department of Internal Medicine, University of Michigan

12/08/06 Lecturer, Internal Medicine Grand Rounds “Immunotherapy in Sepsis: why have we Failed and Where Do We Go from Here”, Department of Internal Medicine, University of Michigan

01/25/07 Lecturer, Pulmonary Research Conference, “Sepsis-induced Immunosuppression: Role of TLR Signalling Cascades”, Division of Pulmonary & Critical Care Medicine, University of Michigan

08/22/07 Lecturer, Noon Conference, “Sepsis”, Department of Internal Medicine, University of Michigan

10/19/07 Invited Discussant, CPC, Department of Internal Medicine, University of Michigan

08/18/08 Lecturer, Immunopathology of Pulmonary Disease Seminar, “Sepsis-induced immunosuppression: Role of toll-like receptor signaling cascades”, Department of Pathology, University of Michigan

11/21/08 Invited Discussant, CPC, Department of Internal Medicine Grand Rounds, University of Michigan

03/24/09 Lecturer, Pulmonary Core Clinical Conference, “Community Acquired Pneumonia, Evolving Concepts”. Division of Pulmonary and Critical Care Medicine, University of Michigan

08/29/12 Lecturer, “Novel Therapeutic Stratigies in Sepsis-induced ALI: From Bench to Bedside”, Research Conference, Division of Pulmonary and Critical Care Medicine, University of Michigan

**Committee, Organizational and Volunteer Service**

**Institutional**

04/1992 Course Planning Committee and Moderator, Advances in Internal Medicine University of Michigan Medical Center

1995-1998 Member, House Staff Selection Committee, Department of Internal Medicine, University of Michigan Medical School

1996-2006 Director, Pulmonary Inpatient Ward, Department of Internal Medicine, University of Michigan Medical Center

2003-2006 Member, Med-Peds House Staff Selection Committee, Departments of Pediatrics and Internal Medicine, University of Michigan Medical Center

2004-2006 Director, Medicine Pulmonary Ventilator Unit, University of Michigan Medical Center

2002-2005 Member, Admissions Committee, University of Michigan Medical School

11/17/2008 Member, Extended Bridging Review Panel, University of Michigan Medical School

2008-2011 Provost Promotion Review Committee, University of Michigan

2011-present Internal Medicine Quality Committee

2012-present Adult Bed Utilization and Service Planning Task Team

2013-present Deans Cardiovascular Center Review Committee

2013-present Chair, Allergy Division Chief Search Committee

**National**

1996-1999 National Councilor, American Federation of Medical Research

1997-1999 Chairman, Membership Committee, American Federation of Medical Research

2004-2008 Scientific Advisory Board, American Lung Asssociation, New York, NY

**National Meeting Session Chairmanships**

05/19/92 Co-Chairman, Cytokines in Lung Inflammation, American Thoracic Society Meetings, Miami Beach, FL

05/23/94 Co-Chairman, Symposium "Macrophage Activation in Lung Injury," American Thoracic Society, Boston, MA

09/17/94 Chair, Cytokine Symposium, Midwest AFCR, Chicago, IL

05/23/95 Co-Chairman, Symposium "Regulation of Macrophage Activation: Genes and Cytokines," American Thoracic Society, Seattle, WA

05/14/96 Co-Chairman, Symposium "Cytokines and Host Defense," American Thoracic Society, New Orleans, LA

04/27/99 Co-Chairman, Symposium, "Recruitment of Inflammatory Cells," American Thoracic Society International Conference, San Diego, CA

05/22/02 Co-Chairman, Symposium, “Genes and Gene Therapy of Pulmonary Infections”, American Thoracic Society International Conference, Atlanta, GA.

05/22/06 Co-Chairman, Mini Symposium, “Pulmonary Innate Immunity.” American Thoracic Society International Conference, San Diego, CA

03/13/08 Moderator, “Inflammatory Injury”, Gordon Conference, Biology of Acute Respiratory Infection, Ventura, CA.

05/18/08 Co-Chairman, Mini Symposium, “Macrophage Signaling in Host Defense Against Infection.” American Thoracic Society International Conference, Toronto, Ontario, Canada

03/19/12 Moderator, “Epithelial Cell Signaling and Immunity in Pneumonia”, Gordon Conference, Biology of Acute Respiratory Infection, Ventura, CA.

05/22/12 Co-Chairman, Mini Symposium, “Mechanism and Outcomes of Celular Autophagy” American Thoracic Society International Conference, San Fancisco, CA.

**Consulting Positions**

1. Novartis Pharmaceutical Corporation, East Hanover, NJ
2. SmithKline Beecham, Philadelphia, PA
3. Abbott Laboratories, Chicago, IL
4. Ortho-McNeil Pharmaceuticals
5. Pfizer Laboratories, Kalamazoo, MI
6. Centocor Research & Development, Inc., Radnor, PA
7. Scientific Advisory Board, Uptake Medical Co., Minneapolis, MN

**Visiting Professorships, Seminars and Extramural Invited Presentations**

**International**

06/27/95 Invited Speaker, "The Role of Chemokines in Bacterial Infection," Fourth

International Chemokine Symposium, Bath, United Kingdom

09/12/97 Lecturer, “The Role of Cytokines in Sepsis,” Immunology Research Group, Emerald Lake Conference, The University of Calgary, Calgary, AB, Canada

03/13/99 Lecturer, "Antimicrobial Immunity," Update in Intensive Care and Emergency Medicine, Brussels, Belgium

11/08/02 Keynote Speaker, "Innate Immunity Against Pulmonary Bacterial Infections", Annual Meeting of the Japanese Respiratory Society, Nagasaki, Japan

11/12/02 Invited Speaker, "Role of PPAR-γ in Sepsis and Acute Lung Injury", Toho University, Tokyo, Japan

3/24/11 Lecturer, “ Sepsis-induced immunosuppression: From bench to bedside”, Research Conference, Division of Pulmonary and Critical Care Medicine, The Conway Institute, University College Dublin, Dublin, Ireland.

**National**

12/18/90 Lecturer, Pulmonary Research Conference, "Pulmonary Chemotactic Cytokine Networks," Yale University, New Haven, CT

12/03/91 Lecturer, Pulmonary Research Conference, "Regulation of Lung Chemotactic Cytokine Networks," Indiana University, Indianapolis, IN

05/16/92 Lecturer, Cytokine and Cytokine Receptor Biology: Update and Applications, "The IL-8 Family of Cytokines," American Thoracic Society Meetings, Miami Beach, FL

05/22/94 Sunrise Seminar, "Cytokines Mediators of Interstitial Lung Disease," American Thoracic Society, Boston, MA

12/16/94 Lecturer, Pulmonary Grand Rounds, "Idiopathic Pulmonary Fibrosis: The University of Michigan Experience," Oregon Health Sciences University, Portland, OR

12/16/94 Lecturer, Pulmonary Research Conference, "Cytokine Networks in Endotoxemia," Oregon Health Sciences University, Portland, OR

03/08/95 Lecturer, "Current Concepts in the Diagnosis and Management of Idiopathic Pulmonary Fibrosis,” Genesys Regional Medical Center, Flint, MI

05/23/95 Lecturer, "Regulation of Macrophage-derived Chemokines: The role of alcohol," American Thoracic Society, Seattle, WA

11/30/95 Lecturer, “Nosocomial Pneumonia in the 1990’s,” Genesys Regional Medical Center, Flint, MI

11/22/96 Lecturer, “The Role of Immunotherapy in Gram-negative Bacterial Pneumonia,” Department of Microbiology and Immunology, Medical College of Ohio, Toledo, OH

02/09/98 Lecturer, “Assessment of Drug-induced Pulmonary Toxicity,” Novartis Pharmaceuticals Corporation, East Hanover, NJ

12/17/98 Lecturer, "Nosocomial Pneumonia in the Post-Antibiotic Era," Internal Medicine Grand Rounds, University of Minnesota, Minneapolis, MN

12/17/98 Lecturer, "The Role of Immunotherapy in Bacterial Pneumonia", Research Conference, VAMC, University of Minnesota, Minneapolis, MN

02/01/99 Lecturer, "Role of Immunotherapy in the Treatment of Pneumonia," Pulmonary Conference, University of Virginia, Charlottesville, VA

03/25/99 Lecturer, Pulmonary Research Conference, "The Role of Cytokines in Lung Innate Immunity," Washington University, St. Louis, MO

04/27/99 Lecturer, "The Role of Cytokines as Mediators of Pulmonary Inflammation in Bacterial Pneumonia," Symposium, American Thoracic Society International Conference, San Diego, CA

12/14/99 Lecturer, “Chemokines as Mediators of Innate Immune Responses in the Lung,” Combined Allergy/Immunology and Pulmonary Grand Rounds, Wayne State University, Detroit, MI

02/16/00 Lecturer, “Regulation and Networking of Pro-inflammatory Cytokines in the Lung,” Cystic Fibrosis Foundation Consensus Conference, Chantilly, VA

04/06/00 Lecturer, "Nosocomial Pneumonia in the Post-antibiotic Era," Medical Grand Rounds, University of Washington, Seattle, WA

04/06/00 Lecturer, "Cytokines in Sepsis: Good Guys or Bad," Respiratory Critical Care Conference, University of Washington, Seattle, WA

03/27/01 Lecturer, "Nosocomial Pneumonia: Evolving Concepts," Infectious Disease Grand Rounds, University of Buffalo, Buffalo, NY

06/22/01 Lecturer, "Role of Chemokines in Innate Immune Responses of the Lung", Department of Pharmacology, University of Illinois School of Medicine, Chicago, IL

12/17/01 Lecturer, "Role of Chemokines in Innate Immunity of the Lung", Center for Alcohol Research, Louisiana State University, New Orleans, Louisiana

12/18/01 Lecturer, "Sepsis-induced Immunosuppression: from Bad to Worse", Department of Medicine, Louisiana State University, New Orleans, Louisiana

03/08/02 Lecturer, "Sepsis-induced Immunosuppression: from Bad to Worse", Department of Medicine, UCLA Medical Center, Los Angeles, CA

05/22/02 Lecturer, “Gene Therapy in Bacterial Pneumonia”, Symposium, Genes and Gene Therapy of Pulmonary Infections, American Thoracic Society International Conference, Atlanta, GA.

05/23/02 Lecturer, “The Systemic Response to Lung Infection”, International Concensus Conference in Intensive Care Medicine, ICU-acquired Pneumonia, Chicago, IL.

10/16/02 Lecturer, "Sepsis-induced Immunosuppression: Role of PPAR-γ", University of Texas, Galveston, Texas.

02/06/03 Lecturer, "Nosocomial Pneumonia in the 21st Century", Tri-State Pulmonary Conference, University of Pittsburgh, Pittsburgh, PA.

02/07/03 Lecturer, "Role of PPAR-γ in Pulmonary Inflammation", Research Conference, University of Pittsburgh, Pittsburgh, PA.

03/11/03 Lecturer, "The Science of Pulmonary Inflammation", Pulmonary Seminar Series, Henry Ford Hospital, Detroit, MI.

09/22/03 Lecturer, "Nosocomial Pneumonia/Sepsis:Evolving Strategies", Texas Club of Internists, Birmingham, MI

10/26/03 Lecturer, "Role of GpG on Lung Innate Immunity in Murine Klebsiella Pneumonia", NIAID Bioterrorism Symposium, Bethesda, MD

09/28/04 Lecturer, “CpG as Immunoadjuvant in Sepsis-induced Immunosuppression”, NIAID Bioterrorism Symposium, Bethesda, MD.

10/18/04 Lecturer, “PPAR-γ as a Regulator of Inflammation and Repair in Acute Lung Injury: Lessons from the Bench”, Pittsburgh Lung Conference on Acute Lung Injury, Pittsburgh, PA.

02/16/05 Lecturer, “Sepsis-induced Immunosuppression: Role of Toll-like Receptor Signaling Cascades”, Research Conference, Department of Immunology & Microbiology, Medical College of Ohio, Toledo, OH.

03/11/05 Lecturer, “Sepsis-induced Immunosuppression: Role of Toll-like Receptor Signaling Cascades”, Pulmonary and Critical Care Research Conference, USC Medical Center, Los Angeles, CA.

04/12/05 Lecturer, “Pneumonia in the ICU: Role of a Failed Immune System”, Internal Medicine Grand Rounds, Emory University, Atlanta, Georgia.

04/12/05 Lecturer, “PPAR-γ as a Regulator of Inflammation and Injury in ALI: Lessons from the Bench”, Pulmonary and Critical Care Research Conference, Emory University, Atlanta, Georgia.

09/21/05 Lecturer, “CpG in the Prevention of Bacterial Pneumonia”, Coley/NIAID Bioterrorism Symposium, Boston, MA.

09/23/05 Lecturer, “PPAR-γ in ALI”, ALI SCCOR Directors Meeting, San Francisco, CA.

11/02/05 Lecturer, “Immunomodulatory Effects of Macrolides”, Pfizer Inflammation Conference, Kalamazoo, MI.

4/10-4/11/06 Member, NHLBI Strategic Planning Committee, Bethesda, MD

05/10/06 Lecturer, “Sepsis-induced Immunosuppression: Role of Toll-like Receptor Signaling Cascades”, Centocor, Radnor, PA.

09/19/07 Lecturer, “Alveolar Macrophage in Pulmonary Host Defense”, Symposium, ICAAC, Chicago, IL

09/28/07 Keynote Speaker, “Sepsis-induced Immunosuppression: Role of Toll-like Receptor Signalling Cascades”, Research Day, Division of Pulmonary & Critical Care Medicine, Ohio State University, Columbus, OH.

03/11/08 Lecturer, “Cytokine Networks in the Infected Lung”, Gordon Conference, Biology of Acute Respiratory Infection, Ventura, CA.

04/30/08 Lecturer, “Sepsis-induced Immunosuppression: Role of Toll-like Receptor Signalling Cascades”, Research Conference, Division of Pulmonary & Critical Care Medicine, Louisiana State University, New Orleans, LA.

11/17/08 Lecturer, “Sepsis induced Immunosuppression: Role of IRAK-M”, Research Conference, Department of Anatomy and Opthamology, Wayne State University, Detroit, MI.

06/19/09 Lecturer, “Sepsis-induced immunosuppression: Role of TLR-mediated epigenetic changes. Research Conference, Division of Pulmonary & Critical Care Medicine, UCLA Medical Center, Los Angeles, CA.

10/30/09 Lecturer, “Sepsis-induced immunosuppression: Role of TLR-mediated epigenetic changes Department of Cell Biology, University of North Dakota, Fargo, ND.

4/14/11 Lecturer, “Sepsis-induced immunosuppression: role of TLR-mediated epigenetic changes”, Research Conference, Department of Anesthesiology, Perioperative & Pain Medicine, Harvard University, Boston, MA.

5/15/11 Lecturer, “Inhibition of toll receptors”, Innate Immunity Symposium, American Thoracic Society International Conference, Denver, CO.

2/14/12 Lecturer, “Sepsis-iduced Immunosuppression: from .Bench to Bedside”. Pulmonary Research Conference, University of Vermont, Burlington, VT.

3/16/12 Lecturer, “Host innate responses in Gram-negative bacterial pneumonia”, Gordon Conference, Biology of Acute Respiratory Infection, Ventura, CA.

**Patents**

6/8/99 U.S. Patent No. 5,909,734. "Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense." Inventor: Marc Peters-Golden, M.D.; Co-Inventor: Theodore J. Standiford, M.D.

**Bibliography**

**Peer-Reviewed Journals and Publications:**

1. Standiford TJ, Morganroth ML. High-frequency ventilation. *Chest* 96:1380-1389, 1989.
2. Kunkel SL, Strieter RM, Chensue SW, Basha M, Standiford TJ, Ham J, Remick DG. Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines. *Prog Clin Biol Res* 349:433-44, 1990.
3. Strieter RM, Chensue SW, Standiford TJ, Basha MA, Showell HJ, Kunkel SL. Disparate gene expression of chemotactic cytokines by human mononuclear phagocytes. *Biochem Biophys Res Comm* 166:886-891, 1990.
4. Strieter RM, Chensue SW, Basha MA, Standiford TJ, Lynch III JP, Kunkel SL. Human alveolar macrophage gene expression of interleukin-8 by TNF-, LPS and IL-1. *Am J Respir Cell Mol Biol* 2:321-326, 1990.
5. Strieter RM, Standiford TJ, Chensue SW, Kasahara K, Kunkel SL. Induction and regulation of interleukin-8 gene expression. *Adv Exp Med Biol* 305:23-30, 1991.
6. Kunkel SL, Standiford TJ, Kasahara K, Strieter RM. Interleukin-8 (IL-8): The major neutrophil chemotactic factor in the lung. *Exp Lung Res* 17:17-23, 1991.
7. Standiford TJ, Strieter RM, Chensue SW, Westwick J, Kasahara K, Kunkel SL. IL-4 inhibits the expression of Interleukin-8 from stimulated human monocytes. *J Immunol* 145:1435-1439, 1990.
8. Strieter RM, Lynch III JP, Basha MA, Standiford TJ, Kasahara K, Kunkel SL. Host responses in mediating in sepsis and ARDS. *Semin Respir Inf* 5:233-247, 1990.
9. Standiford TJ, Strieter RM, Kasahara K, Kunkel SL. Disparate regulation of interleukin-8 gene expression from blood monocytes, endothelial cells, and fibroblasts by interleukin-4. *Biochem Biophys Res Comm* 171:531-536, 1990.
10. Davenport RM, Strieter RM, Standiford TJ, Kunkel SL. Interleukin-8 production in red cell incompatibility. *Blood* 76:2439-2442, 1990.
11. Standiford TJ, Kunkel SL, Basha MA, Chensue SW, Lynch III JP, Toews GB, Strieter RM. Interleukin-8 gene expression by a pulmonary epithelial cell line: A model for cytokine networks in the lung. *J Clin Invest* 86:1945-1953, 1990.
12. Strieter RM, Kasahara K, Allen R, Showell HJ, Standiford TJ, Kunkel SL. Human neutrophils exhibit disparate chemotactic factor gene expression. *Biochem Biophys Res Comm* 173:725-730, 1990.
13. Kunkel SL, Standiford TJ, Kasahara K, Strieter RM. Stimulus-specific induction of monocyte chemotactic protein-1 (MCP-1) gene expression. *Adv Exp Med Biol* 305:65-71, 1991.
14. Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells.  *J Biol Chem* 266:9912-9918, 1991.
15. Standiford TJ, Kunkel SL, Strieter RM. Elevated serum levels of tumor necrosis factor-alpha post bronchoscopy and bronchoalveolar lavage. *Chest* 99:1529-1530, 1991.
16. Kasahara K, Strieter RM, Chensue SW, Standiford TJ, Kunkel SL. Monocyte adherence induces interleukin-8 gene expression. *J Leuk Biol* 50:287-295, 1991.
17. Rolfe MW, Kunkel SL, Standiford TJ, Chensue SW, Allen RM, Evanoff HL, Phan SH, Strieter RM. Pulmonary fibroblast expression of interleukin-8: A model for alveolar macrophage-derived cytokine networking. *Am J Respir Cell Mol Biol* 5:493-501, 1991.
18. Standiford TJ, Kunkel SL, Kasahara K, Milia MJ, Rolfe MW, Strieter RM. IL-8 gene expression from human alveolar macrophages: The role of adherence. *Am J Respir Cell Mol Biol* 5:579-585, 1991.
19. Ham JM, Kunkel SL, Dibb CR, Standiford TJ, Rolfe, MW, Strieter RM. Chemotactic cytokine (IL-8 and MCP-1) gene expression by human whole blood. *Immunol Invest* 20:387-394, 1991.
20. Standiford TJ, Kunkel SL, Rolfe MW, Evanoff H, Strieter RM. Regulation of human alveolar macrophage and blood monocyte-derived IL-8 by PGE2 and dexamethasone. *Am J Respir Cell Mol Biol* 6:75-81, 1992.
21. Standiford TJ, Linsten T, Thompson CB, Strieter RM, Kunkel SL. Interleukin-4 differentially regulates tumor necrosis factor-alpha gene expression by human T lymphocytes and monocytes. *Pathobiology* 60:100-107, 1992.
22. Strieter RM, Chensue SW, Standiford TJ, Lynch III JP, Rolfe MW, Kunkel SL. Host response in granulomatous inflammation of the lung. *Semin Respir Med* 13:149-157, 1992.
23. Rolfe MW, Kunkel SL, Rawens B, Standiford TJ, Strieter RM. Suppression of human alveolar macrophage-derived cytokines by amiloride. *Am J Respir Cell Mol Biol* 6:576-582, 1992.
24. Lynch III JP, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM. Neutrophilic alveolitis in idiopathic pulmonary fibrosis: The role of interleukin-8. *Am Rev Respir Dis* 145:1433-1439, 1992.
25. Moore SA, Strieter RM, Rolfe MW, Standiford TJ, Burdick MD, Kunkel SL. The expression and regulation of human alveolar macrophage-derived interleukin-1 receptor antagonist. *Am J Respir Cell Mol Biol* 67:569-575, 1992.
26. Standiford TJ, Strieter RM. The TNF and IL-1 on sepsis: Good cytokines gone bad. *J Lab Clin Med* 120:179-180, 1992.
27. Strieter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, Becker FS, Chensue SW, Kunkel SL. Cytokine-induced neutrophil-derived interleukin-8. *Am J Path* 141:397-407, 1992.
28. Standiford TJ, Strieter RM, Allen RM, Kunkel SL. IL-7 upregulates IL-8 gene expression from resting and stimulated human blood monocytes. *J Immunol* 149:2035-2039, 1992.
29. Metinko A, Kunkel SL, Standiford TJ, Strieter RM. Anoxia-Hyperoxia induces monocyte-derived interleukin-8. *J Clin Invest* 90:791-798, 1992.
30. Rolfe MW, Kunkel SL, Standiford TJ, Orringer MB, Phan SH, Evanoff HL, Burdick MD, Strieter RM. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide (MCP-1). *Am J Physiol (Lung Cell Mol Physiol)* 263:L536-L545, 1992.
31. Strieter RM, Rolfe MW, Becker FS, Kasahara K, Standiford TJ. Regulation of human alveolar macrophage and blood monocyte-derived TNF and IL-8: The role of PGE2. Dexamethasone, amiloride, and IL-4. *Sarcoidosis* 9 Suppl: 195-198, 1992.
32. Standiford TJ, Rolfe M, Kunkel S, Becker F, Lynch III JP, Orringer M, Phan S, Strieter RM. Altered production and regulation of monocyte chemoattractant protein-1 from pulmonary fibroblasts isolated from patients with idiopathic pulmonary fibrosis. *Chest* 103:121-122S, 1993.
33. Mitchell M, Horneffer M, Standiford TJ. Multiple myeloma complicated by restrictive cardiomyopathy and cardiac tamponade. *Chest* 103:946-947, 1993.
34. Paine III R, Rolfe MW, Standiford TJ, Burdick MD, Barrett J, Strieter RM. MCP-1 expression by rat type II alveolar epithelial cells in primary culture. *J Immunol* 150:4561-70, 1993.
35. Standiford TJ, Kunkel SL, Liebler JM, Burdick MD, Gilbert AR, Strieter RM. The gene expression of MIP-1 from human blood monocytes is inhibited by IL-4. *Am J Respir Cell Mol Biol* 9:192-198, 1993.
36. Kasama T, Strieter RM, Standiford TJ, Burdick MD, Kunkel SL. Expression and regulation of human neutrophil-derived macrophage inflammatory protein-1 alpha (MIP-1). *J Exp Med* 178:63-72, 1993.
37. Wertheim WA, Kunkel SL, Standiford TJ, Burdick MD, Becker FS, Wilke CA, Gilbert AR, Strieter RM. Regulation of neutrophil-derived interleukin-8: The role of prostaglandin E2, dexamethasone, and interleukin-4. *J Immunol 151:2166*-2175, 1993.
38. Kasahara K, Strieter RM, Standiford TJ, Kunkel SL. Adherence in combination with LPS, TNF, or IL-1 is synergistic for the induction of monocyte-derived IL-8.  *Pathobiology* 61:57-66, 1993.
39. Standiford TJ, Rolfe MW, Kunkel SL, Lynch III JP, Burdick MD, Gilbert AR, Orringer MB, Strieter RM. Macrophage inflammatory protein-1 expression in interstitial lung disease. *J Immunol* 151:2852-2863, 1993.
40. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Lukacs NW, Danforth JM, Gilbert AR, Strieter RM. The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. *Am J Pathol* 143:794-803, 1993.
41. Strieter RM, Lukacs NW, Standiford TJ, Kunkel SL. Cytokines and lung inflammation. *Thorax* 48:765-769, 1993.
42. Standiford TJ, Kunkel SL, Strieter RM. Interleukin-8: A major mediator of acute pulmonary inflammation. *Reg Immunol* 5:134-151, 1993.
43. Christensen PJ, Rolfe MW, Standiford TJ, Burdick MD, Toews GB, Strieter RM. Characterization of the production of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) in an allogeneic immune response. *J Immunol* 151:1205-1213, 1993.
44. Rolfe MW, Standiford TJ, Kunkel SL, Burdick MD, Gilbert AR, Moore SA, Lynch JP III, Strieter RM. Interleukin-1 receptor antagonist expression in sarcoidosis. *Am Rev Respir Dis* 148:1378-84, 1993.
45. Van Otteren GM, Standiford TJ, Kunkel SL, Danforth JM, Burdick MD, Abruzzo LV, Strieter RM. The expression and regulation of macrophage inflammatory protein-1-alpha by murine alveolar and peritoneal macrophages. *Am J Respir Cell Mol Biol* 10:8-15, 1994.
46. Liebler JM, Kunkel SL, Burdick MD, Standiford TJ, Rolfe MW, Strieter RM. The production of IL-8 and MCP-1 by peripheral blood monocytes: Disparate responses to PHA and LPS. *J Immunol* 152:241-249, 1994.
47. Standiford TJ, Arenberg DA, Danforth JM, Kunkel SL, Van Otteren GM, Strieter RM. Lipoteichoic acid induces the secretion of interleukin-8 from human blood monocytes: A cellular and molecular analysis. *Infect Immun* 62:119-125, 1994.
48. Strieter RM, Koch AE, Antony VB, Fick RB Jr., Standiford TJ, and Kunkel SL. The immunopathology of chemotactic cytokines: The role of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1). *J Lab Clin Med* 123:183-197, 1994.
49. Danforth JM, Strieter RM, Arenberg DA, Kunkel SL, Van Otteren GM, Standiford TJ. Induction of MIP-1 lipoteichoic acid. *J Clin Immunol Immunopath* 74:77-83, 1995.
50. Van Otteren GM, Strieter RM, Kunkel SL, Paine III R, Danforth JM, Burdick MD, Standiford TJ. Compartmentalized expression of RANTES in murine model of endotoxemia. *J Immunol* 154:1900-1908, 1995.
51. Arenberg DA, Kunkel SL, Burdick MD, Standiford TJ, Strieter RM. Regulation of monocyte-derived interleukin-1 receptor antagonist by cisplatinum. *Cytokine* 7:89-96, 1995.
52. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch III JP, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM. Interleukin-1 receptor antagonist protein is increased in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 151:1965-1973, 1995.
53. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. *J Immunol* 155:722-729, 1995.
54. Standiford TJ, Kunkel SL, Lukacs NW, Greenberger MJ, Danforth JM, Kunkel RG, Strieter RM. Macrophage inflammatory protein-1 mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. *J Immunol* 155:1515-1524, 1995.
55. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia: Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. *J Immunol* 155:2222-2229, 1995.
56. Massey KD, Strieter RM, Kunkel SL, Danforth JD, Standiford TJ. Cardiac myocytes release leukocyte stimulatory factors. *Am J Physiol: Heart and Circ* 269:980-987, 1995*.*
57. Smith RE, Strieter RM, Phan SH, Standiford TJ, Lukacs NW, Kunkel SL. A role for CC chemokines in fibrotic lung disease. *J Leuk Biol* 57:782-787, 1995.
58. Van Otteren GM, Standiford TJ, Kunkel SL, Danforth JM, Strieter RM. Alterations of ambient oxygen concentration modulate the expression of tumor necrosis factor and macrophage inflammatory protein 1 alpha from murine alveolar macrophages. *Am J Respir Cell Mol Biol* 13:399-409, 1995.
59. Huffnagle GB, Strieter RM, Standiford TJ, McDonald RD, Burdick M, Kunkel SL, Toews GB. Monocyte chemotactic protein-1 (MCP-1): A critical mediator of CD4+ T cells in macrophage recruitment into the lungs during a *Cryptococcus neoformans* infection*. J Immunol* 155:4790-4797, 1995.
60. Gyetko MR, Sitrin RG, Fuller JA, Todd RF, Petty H, Standiford TJ. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. *J Leuk Biol* 58:533-538, 1995.
61. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of MIP-2 decreases neutrophil influx in a murine model of *Klebsiella* pneumonia. *J Infect Dis* 173:159-165, 1996.
62. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM. Expression and regulation of chemokines in bacterial pneumonia. *J Leuk Biol* 59:24-28; 1996.
63. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. The good, the bad, and the ugly: the role of chemokines in models of human disease*. J Immunol* 156:3583-3586, 1996.
64. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. *FEMS Immunol Med Microbiol* 15:181-187, 1996.
65. Standiford TJ, Strieter RM, Greenberger MJ, Kunkel SL. Expression and regulation of chemokines in acute bacterial pneumonia. *Biol Signals* 5:203-208, 1996.
66. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, Danforth JM, Standiford TJ. IL-12 gene therapy protects mice in lethal *Klebsiella* pneumonia. *J Immunol* 157:3006-3012, 1996.
67. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines is related to severity and mortality of murine sepsis*. Infect Immun* 64:4733-4738, 1996.
68. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Standiford TJ. TNF mediates lung antibacterial host defense in murine *Klebsiella* pneumonia*. Infect Immun* 64:5211-5218, 1996.
69. Bailie MB, Standiford TJ, Laichalk LL, Strieter RM, Peters-Golden ML. Leukotriene-deficient mice manifest enhanced lethality from *Klebsiella* pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J Immunol* 157:5221-5224, 1996.
70. Marinella MA, Standiford TJ. Empyema necessitans due to *Streptococcus milleri*. *J Clin Infect Dis* 23:203-204,1996.
71. Lukacs NW, Standiford TJ, Chensue SW, Kunkel RG, Strieter RM, Kunkel SL. C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation*. J Leuk Biol* 60:573-578, 1996.
72. Elner VM, Elner SG, Standiford TJ, Lukacs NW, Strieter RM, Kunkel SL. Interleukin-7 (IL-7) induces retinal pigment epithelial cell MCP-1 and IL-8. *Exp Eye Res* 63:297-303, 1996.
73. Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, Chen G-H, Standiford TJ. Nitric oxide is required for effective innate immunity against *Klebsiella* *pneumoniae.* *Infect Immun* 65:1870-1875, 1997.
74. Broug-Holub E, Toews GB, van Iwaarden JF, Strieter RM, Kunkel SL, Paine R, Standiford TJ. Alveolar macrophages are required for protective pulmonary defenses in murine *Klebsiella* pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. *Infect Immun* 65:1139-1146, 1997.
75. Zisman DA, Kunkel SL, Strieter RM, Tsai WC, Bucknell K, Wilkowski J, Standiford TJ. MCP-1 protects mice in lethal endotoxemia *J Clin Invest* 99:2832-2836, 1997.
76. Keane MP, Standiford TJ, Strieter RM. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. *Eur Respir J* 10:1199-1202, 1997.
77. Standiford TJ, Huffnagle GB. Cytokines in host defense against pneumonia. *J Invest Med* 45: 335-345, 1997.
78. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Elevated macrophage inflammatory protein-2 in severe murine peritonitis increases neutrophil recruitment and mortality. *Infect Immun* 65:3847-3851, 1997.
79. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J, Wilkowski J, Bucknell K, Standiford TJ. Anti-IL-12 therapy in sepsis: disparate effects in murine models of endotoxemia and *Escherichia coli* peritoneal sepsis. *Shock* 8:349-356, 1997.
80. Standiford TJ, Danforth JM. Ethanol feeding inhibits proinflammatory cytokine expression from murine alveolar macrophage ex-vivo. *Alcoh Clin Exp Res* 21:1212-1217, 1997.
81. Hogaboam, CM, Steinhauser ML, Schock H, Lukacs N, Strieter RM, Standiford T, Kunkel SL. Therapeutic effects of nitric oxide inhibition during experimental fecal peritonitis. *Infect Immun* 66:650-655, 1998.
82. O’Brien AD, Standiford TJ, Christensen PJ, Wilcoxen SE, Paine R III. Chemotaxis of alveolar macrophages in response to signals derived from alveolar epithelial cells. *J Lab Clin Med 131:417*-424, 1998.
83. Laichalk LL, Bucknell KA, Huffnagle GB, Wilkowski JM, Moore TA, Romanelli RJ, Standiford TJ. The intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. *Infect Immun 66*:2822-2826, 1998.
84. Zisman DA, Strieter RM, Kunkel SL, Tsai WC, Wilkowski JM, Bucknell KA, Standiford TJ. Ethanol feeding impairs innate immunity and alters the expression of Th1- and Th2- phenotype cytokines in murine *Klebsiella* pneumonia. *Alcoh Clin Exp Res* 22:621-627, 1998.
85. Hogaboam, C, Kunkel SL, Strieter RM, Taub DD, Lincoln, P, Standiford TJ, Lukacs, NW. Novel role of transmembrane SCF for mast cell activation and eotaxin production in mast cell-fibroblast interactions*. J Immunol* 160:6166-6171, 1998.
86. Tsai TC, Strieter RM, Wilkowski JM, Bucknell KA, Burdick MD, Lira SA, Standiford TJ. Lung-specific transgenic expression of KC enhances resistance to *Klebsiella* *pneumoniae* in mice. *J Immunol* 161:2435-2440, 1998.
87. Mancuso P, Standiford TJ, Marshall T, Peters-Golden ML. 5-Lipoxygenase reaction products modulate alveolar macrophage phagocytosis of *Klebsiella pneumoniae*. *Infect Immun* 66:5140-5146, 1998.
88. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. *J Immunol* 162:392-399, 1999.
89. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-α in pulmonary host defense in murine invasive aspergillosis. *J Immunol* 162:1633-1640, 1999.
90. Standiford TJ, Wilkowski JM, Sisson T, Hattori N, Mehrad B, Bucknell KA, Moore TA. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. *Human Gene Therapy* 10:899-909, 1999.
91. Mehrad B, Standiford TJ. Role of cytokines in pulmonary antimicrobial host defense. *Immunol Res* 20:15-27, 1999.
92. Strieter RM, Kunkel SL, Keane MP, Standiford TJ. Chemokines in lung injury. *Chest* 116:103S-110S, 1999.
93. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC, Standiford TJ. On the physiological role(s) of the paraoxonases. *Chemico-Biological Interactions* 119-120:379-388, 1999.
94. O’Brien AD, Standiford TJ, Bucknell KA, Wilcoxen SE, Paine R III. Role of alveolar epithelial cell intercellular adhesion molecule-1 in host defense against *Klebsiella pneumoniae*. *Am J Physiol 276:L961*-970, 1999.
95. Mehrad B, Strieter RM, Moore TA, Tsai WC, Standiford TJ. CXC chemokine receptor-2 ligands are required components of neutrophil-dependent host defense in invasive pulmonary aspergillosis. *J Immunol* 163:6086-6094, 1999.
96. Moore TA, Newstead MW, Strieter RM, Mehrad B, Beaman BL, and Standiford TJ. Bacterial clearance and survival are dependent on CXC chemokine receptor-2 ligands in a murine model of pulmonary *Nocardia* *asteroids* infection. *J Immunol* 164:908-915, 2000.
97. Standiford TJ, Tsai WC, Mehrad B, Moore TA. Cytokines as targets of immunotherapy in bacterial pneumonia. *J Lab Clin Med* 135:129-138, 2000.
98. Matsukawa A., Lukacs NW, Standiford TJ, Chensue SW, Kunkel SL. Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of TH1 and TH2 type responses in vivo. *J Immunol* 164:1699-1704, 2000.
99. Hogaboam CM, Blease K, Mehrad B, Steinhauser ML, Standiford TJ, Kunkel SL, Lukacs NW. Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by *Aspergillus fumigatus. Am J Pathol* 156:723-732, 2000.
100. Tsai, WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine *Pseudomonas aeruginosa* pneumonia. *Infect Immun* 68:289-4296, 2000.
101. Mehrad B, Moore TA, Standiford TJ. Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. *J Immunol* 165:962-968, 2000.
102. Blease K, Mehrad B, Standiford TJ, Lukacs NW, Gosling J, Boring L, Charo IF, Kunkel SL, Hogaboam CM. Enhanced pulmonary allergic response to *Aspergillus* in CCR2-/- mice. *J Immunol* 165:2603-2611, 2000.
103. Moore TA, Moore B, Standiford TJ. Gamma delta T cells are required for protective innate responses in murine *Klebsiella* pneumonia. *J Immunol* 165:2643-2650, 2000.
104. Chen GH, Reddy RC, Newstead MW, Tateda K, Kyasapura BL, Standiford TJ. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. *J Immunol* 165:6496-6503, 2000.
105. Tateda K, Moore TA, Deng, JC, Newstead MW, Zeng X, Matsukawa A, Swanson MS, Yamaguchi, Standiford TJ. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of *Legionella pneumophila* pneumonia. *J Immunol* 166:3355-3361, 2001.
106. Chen S-C, Mehrad B, Deng JC, Vassileva G, Manfra DJ, Cook DN, Wiekowski MT, Zlotnik A, Standiford TJ, Lira SA. Impaired pulmonary host defense in mice lacking expression of the CXC chemokine Lungkine. *J Immunol* 166:3362-3368, 2001.
107. Tateda K, Moore TA, Newstead MW, Tsai WC, Zeng X, Deng JC, Chen C, Reddy R, Yamaguchi, Standiford TJ. Chemokine-dependent neutrophil recruitment in a murine model of Legionella pneumonia: potential role of neutrophils as immunoregulatory cells. *Infect Immun* 69:2017-2024, 2001.
108. Reddy RC, Chen GH, Newstead MW, Moore TA, Zeng X, Tateda K, Standiford TJ. Alveolar macrophage deactivation in murine septic peritonitis: role of IL-10. *Infect Immun* 69:1394-1401, 2001.
109. Blease K, Mehrad B, Lukacs NW, Kunkel SL, Standiford TJ, Hogaboam CM. Antifungal and airway remodeling roles for murine monocyte chemoattractant protein-1/CCL2 during pulmonary exposure to Aspergillus fumigatus conidia*. J Immunol* 166:1832-1842, 2001.
110. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, Mancuso P, Peters-Golden M, Standiford TJ. Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. *Am J Physiol* *Lung Cell Mol Physiol.* 281: L537-543, 2001.
111. Lindell DM, Standiford TJ, Mancuso P, Leshen Z, Huffnagle GB. Macrophage inflammatory protein 1α/CCL3 is required for clearance of an acute *Klebsiella pneumoniae* pulmonary infection. *Infect Immun* 69:6364-69, 2001.
112. Deng JC, Tateda K, Zeng X, Standiford TJ. Transient transgenic expression of IFN-γ promotes *Legionella pneumophila* clearance in immunocompetent hosts. *Infect Immun* 69:6382-90, 2001.
113. Rijneveld AW, VanDen Dobbelsteen GP, Florquin S, Standiford TJ, Speelman P, Van Alphen L, Van der Poll T. Role of interleukin-6 and macrophage inflammatory protein 2 in pneumolysin induced lung inflammation in mice. *J Infect Dis* 185:123-26. 2002.
114. Gao X, Standiford TJ, Rahman A, Newstead M, Holland SM, Dinauer MC, Liu Q, Malik AB. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by gram negative sepsis: studies in 47phox -/- and gp91phox -/- mice. *J Immunol* 168:3974-82, 2002.
115. Skidgel RA, Brovkovych V, Rahman A, Jho D, Predescu S, Standiford TJ, Malik AB. Nitric oxide stimulates macrophage inflammatory protein-2 expression in sepsis. *J Immunol* 169:2093-2101, 2002.
116. Moore TA, Perry ML, Getsoian AG, Newstead MW, Standiford TJ. Divergent role of IFN-γ in a murine model of pulmonary versus systemic *Klebsiella pneumoniae* infection. *Infect Immun* 70:6310-6318, 2002.
117. Tateda K, Deng JC, Moore TA, Newstead MW, Paine R III, Kobayashi N, Yamaguchi K, Standiford TJ. Hyperoxia mediates acute lung injury and increased lethality in murine *Legionella* pneumonia: The role of apoptosis. *J Immunol* 170:4209-16, 2003.
118. Zeng X, Moore TA, Newstead MW, Hernandez-Alcoceba R, Tsai WC, Standiford TJ. Intrapulmonary expression of macrophage inflammatory protein 1α (CCL3) induces neotrophil and NK cell accumulation and stimulates innate immunity in murine bacterial pneumonia. *Infect Immun* 71:1306-15, 2003.
119. Moore TA, Perry ML, Getsoian AG, Monteleon CL, Cogen AL, Standiford TJ. Increased mortality and dysregulated cytokine production in tumor necrosis factor receptor 1-deficient mice following systemic *Klebsiella pneumoniae* infection. *Infect Immun* 71:4891-4900, 2003.
120. Moore TA, Lau H, Cogen AL, Monteleon CL, Standiford TJ. Anti-TNFα therapy during murine *Klebsiella pneumoniae* bacteremia: increased mortality in the absence of liver injury. *Shock* 20:309-315, 2003.
121. Ojielo CI, Cooke K, Mancuso P, Standiford TJ, Olkiewicz KM, Clouthier S, Toews GB, Moore BB. Defective phagocytosis and clearance of *Pseudomonas aeruginosa* in the lung following bone marrow transplantation. *J Immunol* 171:4416-24, 2003.
122. Tateda K, Ishii Y, Horikawa M, Matsumoto T, Miyairi S, Pechere JC, Standiford TJ, Ishiguro M, Yamaguchi K. The *Pseudomonas* autoinducer N-3-Oxododecanoyl homoserine lactone accelerates apoptosis in macrophophages and neutrophils. *Infect Immun* 71:5785-93, 2003.
123. Younger JG, Shankar-Sinha S, Mickiewicz M, Brinkman AS, Sarma VJ, Younkin EM, Standiford TJ, Ward PA. Murine complement interactions with *Pseudomonas aeruginosa* and their consequences during pneumonia. *Am J Resp Cell Mol Biol* 29:432-28, 2003*.*
124. Baleeiro CEO, Wilcoxen SE, Morris SB, Standiford TJ, Paine R III. Sublethal hyperoxia impairs pulmonary innate immunity. *J Immunol* 171:955-63, 2003.
125. Hasday JD, Garrison A, Singh IS, Standiford TJ, Ellis GS, Rao S, He JR, Rice P, Frank M, Goldblum SE, Viscardi RM. Febrile-range hyperthermia augments pulmonary neutrophil recruitment and amplifies pulmonary oxygen toxicity. *Am J Pathol* 162:2005-17, 2003.
126. Keshamouni VG, Reddy RC, Arenberg DA, Binju J, Thannickal VJ, Kalemkerian GP, Standiford TJ. Peroxisome proliferators-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. *Oncogene* 23:100-08, 2004.
127. Shankar-Sinha S, Valencia GA, Janes BK, Rosenberg JK, Whitfield C, Standiford TJ, Younger JG. Klebsiella pneumoniae O-antigen contributes to bacteremia and lethality during murine pneumonia. *Infect Immun* 72:1423-30, 2004.
128. Reddy RC, Keshamouni VG, Jaigirdar SH, Zeng X, Leff T, Thannickal VJ, Standiford TJ. Deactivation of murine alveolar macrophages by peroxisome proliferators-activated receptor gamma ligands. *Am J Physiol Lung Cell Mol Physiol* 286:L613-19, 2004.
129. Nara C, Tateda K, Matsumoto T, Ohara A, Miyazaki S, Standiford TJ, Yamaguchi K. *Legionella*-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-α. *J Med Microbiol* 53:727-33, 2004.
130. Deng JC, Zeng X, Newstead M, Moore TA, Tsai WC, Thannickal VJ, Standiford TJ. STAT4 is a critical mediator of early innate immune responses against pulmonary *Klebsiella* infection. *J Immunol* 173:4075-83, 2004.
131. Deng JC, Moore TA, Newstead MW, Zeng X, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary *Klebsiella* infection. *J Immunol* 173:5148-55, 2004.
132. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K, Hershenson MB, Standiford TJ. Azithromycin blocks neutrophil recruitment in *Pseudomonas* endobronchial infection. *Am J Resp Crit Care* *Med* 170:1331-9, 2004.
133. Nelson S, Standiford TJ. Pulmonary host defenses. *Sem Resp Crit Care Med* 25:1-2, 2004.
134. Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, Standiford TJ, Thannickal VJ. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. *Am J Pathol* 166:367-75, 2005.
135. Zeng X, Moore TA, Newstead MW, Deng JC, Lukacs NW, Standiford TJ. IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. *J Interferon Cytokine Res* 25:103-12, 2005.
136. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford, TJ. PPAR-γ activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non small cell lung cancer. *Neoplasia* 7:294-301, 2005.
137. Yoshizawa S, Tateda K, Matsumoto T, Gondaira F, Miyazaki S, Standiford TJ, Yamaguchi K. Legionella pneumophila evades IFN-γ-mediated growth suppression through IL-10 induction in bone marrow-derived macrophages. *Infect Immun* 73: 2709-17, 2005.
138. Moore TA, Lau HY, Cogen AL, Standiford TJ. Defective innate antibacterial host responses during murine *Klebsiella pneumoniae* bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. *Clin Infect Dis* 41:Suppl. 3: S213-7, 2005.
139. Standiford TJ, Keshamouni VG, Reddy RC. PPAR-γ as a regulator of lung inflammation and repair. *Proc Am Thorac Soc* 2:226-31, 2005.
140. Zeng X, Moore TA, Newstead MW, Deng JC, Kunkel SL, Luster AD, Standiford TJ. IP-10, but not MIG, promotes protective Type 1 immunity in murine *Klebsiella* Pneumonia. *Infect Immun* 73:8226-36, 2005.
141. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, Easley RB, McVerry B, Tuder RM, Standiford TJ, Brower R, Barnes KC, Garcia JGN. Pre-B-cell colony enhancing factor as a potential novel biomarker in acute lung injury. *Am J Resp Crit Care Med* 171:298-9, 2005.
142. Horowitz JC, Cui Z, Moore TA, Meier TR, Reddy, RC, Toews GB, Standiford TJ, Thannickal VJ. Constitutive activation of pro-survival signaling in alveolar mesenchymal cells isolated from patients with non-resolving acute respiratory distress syndrome. *Am J Physiol* *Lung Cell Mol Physiol* 290:L415-425. 2006.
143. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenberg DA, Reddy RC, Sudhakar A, Thannickal VJ, Standiford TJ, Andrews PC, Omenn GS. Differential protein expression profiling by ITRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. *J Proteome Res* 5:1143-54, 2006.
144. Mehrad B, Park SJ, Standiford TJ, Zhu J, Mohan C. The lupus susceptibility locus, Sle3, mediates enhanced resistance to bacterial infections. *J Immunol* 176:3233-9, 2006.
145. Ballinger MN, Paine R 3rd, Serezani CH, Aronoff DM, Choi ES, Standiford TJ, Toews GB, Moore BB. Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with *Pseudomonas aeruginosa*. *Am J Respir Cell Mol Biol* 34:766-74, 2006.
146. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell R, Standiford TJ. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. *J Clin Invest* 116:2532-42, 2006.
147. Fligiel SEG, Standiford T, Fliegiel HM, Tashkin D, Streiter RM, Warner RL, Johnson KT, Varani J. Matrix metalloproteinases (MMP’s) and MMP inhibitors in acute lung injury *Hum Pathol* 37:422-30, 2006.
148. Miyairi S, Tateda K, Huse ET, Ueda C, Takabatake T, Saito H, Ishii Y, Standiford TJ, Yamaguchi K. Immunization with carrier-conjugated 3-oxo-C12-homoserine lactone protects mice from lethal *Pseudomonas aeruginosa* lung infection. *J Med Microbiol* 55:1381-87, 2006.
149. Fuse ET, Tateda K, Kikuchi Y, Matsumoto T, Gondaira F, Azuma A, Kudoh S, Standiford TJ, Yamaguchi K. Role of Toll-like receptor 2 in recognition of *Legionella pneumophila* in a murine pneumonia model.  *J Med Microbiol* 56:305-12, 2007.
150. Karaolis DKR, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, Bhan U, Liang H, Standiford TJ. c-di-GMP stimulates protective innate immunity in bacterial pneumonia. *Infect Immun* 75:4942-50, 2007.
151. Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford, TJ. TLR9 is required for protective innate immunity in gram-negative bacterial pneumonia: role of dendritic cells. *J Immunol* 179:3937-46, 2007.
152. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Chensue SW, Kunkel SL. TLR9 activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response. *Eur J Immunol* 37:2847-55, 2007.
153. Narala VR, Gangireddy SR, Smith MR, Berlin AA, Standiford TJ, Lukacs NW, Reddy RC. Pioglitazone is as effective as dexamethasone in a murine model of cockroach allergen-induced asthma. *Respir Res* 8:90-100, 2007. PMC2231357
154. Smith M, Standiford TJ, Reddy RC. PPARs in alveolar macrophage biology*. PPAR Res* 3; 1-12, 2007. PMCID: PMC2066181
155. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy R. PPAR-agonists inhibit pro-fibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* 294: L891-901, 2008. PMID: 18162602
156. Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ. TLR9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by *Legionella* pneumophila. *Infect Immun* 76:2895-2904, 2008. PMC2446723
157. Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian G, Standiford TJ, Keshamouni VG. Chemotherapeutic drugs induce PPAR- expression and show sequence-specific synergy with PPAR- ligands in inhibition of non-small-cell lung cancer. *Neoplasia* 10:597-603, 2008. PMC2386544
158. Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW, Standiford TJ. Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferators-activated receptor-.  *Blood* 112:4250-4258, 2008. PMC2582007
159. Jarvinen L, Badri L, Wettlaufer S, Ohtsuka T, Standiford TJ, Toews GB, Pinsky DJ, Peters-Golden M, Lama VN. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. *J Immunol* 181:4389-4396, 2008. PMID: 18768898
160. Hayakawa K, Tateda K, Fuse ET, Matsumoto T, Akasaka Y, Ishii T, Nakayama T, Taniguchi M, Kaku M, Standiford TJ, Yamaguchi K. Paradoxically high resistance of natural killer T (NKT) cell-deficient mice to Legionella pneumophila: another aspect of NKT cells for modulation of host responses. *J Med Microbiol* 57:1340-1348, 2008. PMID: 18927410
161. Bhan U, Cornicelli MD, Standiford TJ. Cytokine networks in the infected lung.  *Expert Rev Resp Med* 2:739-752, 2008. PMID: 20477236
162. Ramaprakash H, Ito T, Standiford TJ, Kunkel SL, Hogaboam CM. TLR9 modulates immune responses to Aspergillus fumigatus conidia in immunodeficient and allergic mice. *Infect Immun* 77:108-119, 2009. PMC2612288
163. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, Chensue SW, Kunkel SL. TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4.  *J Clin Invest* 119:33-46, 2009. PMC2613456
164. Keshamouni VG, Jagtap P, Michailidis G, Strahler JR, Kuick R, Panagiotis P, Krishnapuram R, Srirangam A, Standiford TJ, Andrews PC, Omenn GS. Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF--induced epithelial-mesenchymal transition. *J Proteome Res* 8:35-47, 2009. PMID: 19118450
165. Sun L, Guo RF, Newstead MW, Standiford TJ, Macariola DR, Shanley TP. Effect of IL-10 on neutrophil recruitment and survival after *Pseudomonas aeruginosa* challenge. *Am J Respir Cell Mol Biol* 41:76-84, 2009. PMC2701962
166. Kikuchi Y, Tateda K, Fuse ET, Matsumoto T, Gotoh N, Fukushima J, Takizawa H, Nagase T, Standiford TJ, Yamaguchi K. Hyperoxia exaggerates bacterial dissemination and lethality in *Pseudomonas aeruginosa* pneumonia. *Pulm Pharmacol Ther* 22:333-339, 2009. PMID: 19162211
167. Ito T, Schaller M, Raymond T, Joshi AD, Coelho AL, Frantz FG, Carson Iv WF, Hogaboam CM, Lukacs NW, Standiford TJ, Phan SH, Chensue SW, Kunkel SL. Toll-like receptor 9 activation is a key mechanism for the maintenance of chronic lung inflammation. *Am J Respir Crit Care Med* 12:1227-1238, 2009. PMC2796734
168. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA, and the NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. *Chest* 137:288-296, 2010. PMC2816641
169. Reddy RC, Standiford TJ. Effects of sepsis on neutrophil chemotaxis. *Curr Opin Hematol* 17:18-24, 2010. Review. PMID: 19864946
170. Seki M, Kohno S, Newstead MW, Zeng X, Bhan U, Lukacs NW, Kunkel SL, Standiford TJ. Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia.  *J Immunol* 184:1410-1418, 2010. PMID: 20042589
171. Rosada RS, Moreira AP, Frantz FG, Puri RK, Rahman A, Standiford TJ, Zárate-Bladés CR, Silva CL, Hogaboam CM. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to *Pseudomonas aeruginosa* exotoxin A. *PLoS One*. 5:e8721, 2010. PMC2806906
172. Smith MR, Gangireddy SR, Narala VR, Hogaboam CM, Standiford TJ, Christensen PJ, Kondapi AK, Reddy RC. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. *Am J Physiol Lung Cell Mol Physiol* 298:L616-L625, 2010. PMC2867399
173. Bhan U, Ballinger MN, Zeng X, Newstead MJ, Cornicelli MD, Standiford TJ. Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia. *PLoS One* 5:e9896, 2010. PMC2845620
174. Hubbard LL, Ballinger MN, Thomas PE, Wilke CA, Standiford TJ, Flavell RA, Moore BB. A role for IRAK-M in PGE2-induced immunosuppression post-bone marrow transplantation. *J Immunol* 184:6299-6308, 2010. PMC in process. NIHMSID#254121
175. Yu F, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, Gao N, Yoon S, Gallo RL, Standiford TJ. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin related antimicrobial peptide*. J Immunol* 185:1142-1149, 2010 PMID: 20566829.
176. Zhang Y, Wang F, Bhan U, Huffnagle GB, Toews GB, Standiford TJ, Olszewski MA. TLR9 signaling is required for generation of the adaptive immune protection in *Cryptococcus neoformans* infected lungs.  *Am J Path* 177:754-765, 2010. PMC2913381
177. Lyn-Kew K, Rich E, Zeng X, Wen H, Kunkel SL, Newstead MW, Bhan U, Standiford TJ. IRAK-M Regulates chromatin remodeling in lung macrophages during experimental sepsis. *PLoS One* 5: e11145, 2010. PMC2886833
178. Kumar A, Gao N, Standiford TJ, Gallo RL, Yu FS. Topical flagellin protects the injured corneas from *Pseudomonas aeruginosa* infection. *Microbe Infect* 12:978-989, 2010. PMID: 20601077
179. Reddy RC, Standiford TJ. Nrf2 and PPAR-γ: PPARtnering against oxidant-induced lung injury. *Am J Respir Crit Care Med* 182:134-135, 2010. PMID: 20634499
180. Ballinger M, Standiford TJ. Post-influenza bacterial pneumonia: host defenses gone awry. *J Interferon Cytokine Res* 30:643-652, 2010. PMID 20726789
181. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG. Peroxisome proliferator-activated receptor-{gamma} activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. *Mol Cancer Ther* 9:3221-3232, 2010. PMID: 21159608
182. Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine R 3rd, Standiford TJ. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative metabolomics and computational analysis. *Am J Physiol Lung Cell Mol Physiol* 300:L4-L11, 2011. PMID: 20726789.
183. Mendez MP, Monroy YK, Du M, Preston AM, Tolle LB, Lin Y, VanDussen KL, Samuelson LC, Standiford TJ, Curtis JL, Beck JM, Christensen PJ, Paine R III. Overexpression of sICAM-1 in the alveolar epithelial space results in an exaggerated inflammatory response and early death in gram negative pneumonia. *Respir Res* 12:1-12, 2011. PMID: 21247482
184. Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF--induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. *Oncogene* 30:2475-84, 2011. PMC 3102782
185. Reka AK, Goswami MT, Krishnapuram R, Standiford TJ, Keshamouni VG. Molecular corss-regulation between PPAR- and other signaling pathways: Implications for lung cancer therapy. *Lung Cancer* 72:154-159, 2011. PMC 3075310
186. Serkova NJ, Standiford TJ, Stringer KA. The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. *Am J Resp Crit Care Med* 184:647-55, 2011. PMC3208597
187. Bhan U, Newstead MJ, Zeng X, Ballinger MN, Standiford LR, Standiford TJ. Stachybotrys chartarum-induced hypersensitivity pneumonitis is TLR9 dependent. *Am J Pathol* 179:2779-87, 2011. PMC3260863
188. Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. *J Thorac Oncol* 6:1784-92, 2011. PMC3196823
189. Paine III R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC. A randomized trial of recombinant human GM-CSF for patients with acute lung injury. *Crit Care Med* 40:90-97, 2011. PMC3242850
190. Standiford LR, Standiford TJ, Newstead MW, Zeng X, Ballinger MN, Kovach MA, Reka AK, Bhan U. TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia. *Am J Physiol Lung Cell Mol Physiol* 302:L447-54, 2011: PMC3311511.
191. Surendran N, Hiltbold E. Heid E, Akira S, Standiford TJ, Sriranganathan N, Boyle S, Zimmerman K, Makris M, Witonsky S. Role of TLRs in brucella mediated murine DC activation in vitro and clearance of pulmonary infection in vivo. *Vaccine* 30:1502-12, 2012. PMID:22234268 (PMC in process)
192. Qiu Y, Zeltzer S, Zhang Y, Wang F, Chen GH, Dayrit J, Murdock BJ, Bhan U, Toews GB, Osterholzer JJ, Standiford TJ, Olszewski, MA. Early induction of CCL7 downstream of TLR9 signaling promotes the development of robust immunity to cryptococcal infection. *J Immunol* 188:3940-48, 2012. PMC3324623
193. Standiford TJ, Keshamouni VG. Breaking the tolerance for tumor: targeting negative regulators of TLR signaling. [*Oncoimmunology*](http://www.ncbi.nlm.nih.gov/pubmed/22737610) 1:340-345, 2012. PMC3382869
194. [Ballinger MN](http://www.ncbi.nlm.nih.gov/pubmed?term=Ballinger%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Newstead MW](http://www.ncbi.nlm.nih.gov/pubmed?term=Newstead%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Zeng X](http://www.ncbi.nlm.nih.gov/pubmed?term=Zeng%20X%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Bhan U](http://www.ncbi.nlm.nih.gov/pubmed?term=Bhan%20U%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Horowitz JC](http://www.ncbi.nlm.nih.gov/pubmed?term=Horowitz%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Moore BB](http://www.ncbi.nlm.nih.gov/pubmed?term=Moore%20BB%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Pinsky DJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Pinsky%20DJ%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Flavell RA](http://www.ncbi.nlm.nih.gov/pubmed?term=Flavell%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=22661086), [Standiford TJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Standiford%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=22661086). TLR Signaling Prevents Hyperoxia-Induced Lung Injury by Protecting the Alveolar Epithelium from Oxidant-Mediated Death. [*J Immunol*](http://www.ncbi.nlm.nih.gov/pubmed/22661086) 189:356-64, 2012. PMC3529412
195. [Kovach MA](http://www.ncbi.nlm.nih.gov/pubmed?term=Kovach%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Ballinger MN](http://www.ncbi.nlm.nih.gov/pubmed?term=Ballinger%20MN%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Newstead MW](http://www.ncbi.nlm.nih.gov/pubmed?term=Newstead%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Zeng X](http://www.ncbi.nlm.nih.gov/pubmed?term=Zeng%20X%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Bhan U](http://www.ncbi.nlm.nih.gov/pubmed?term=Bhan%20U%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Yu FS](http://www.ncbi.nlm.nih.gov/pubmed?term=Yu%20FS%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Moore BB](http://www.ncbi.nlm.nih.gov/pubmed?term=Moore%20BB%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Gallo RL](http://www.ncbi.nlm.nih.gov/pubmed?term=Gallo%20RL%5BAuthor%5D&cauthor=true&cauthor_uid=22634613), [Standiford TJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Standiford%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=22634613). Cathelicidin-related antimicrobial Peptide is required for effective lung mucosal immunity in gram-negative bacterial pneumonia. [*J Immunol*](http://www.ncbi.nlm.nih.gov/pubmed/22634613) 189:304-11, 2012. PMC 3566644
196. [Finigan JH](http://www.ncbi.nlm.nih.gov/pubmed?term=Finigan%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Mishra R](http://www.ncbi.nlm.nih.gov/pubmed?term=Mishra%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Vasu VT](http://www.ncbi.nlm.nih.gov/pubmed?term=Vasu%20VT%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Silveira LJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Silveira%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Nethery DE](http://www.ncbi.nlm.nih.gov/pubmed?term=Nethery%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Standiford TJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Standiford%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Burnham EL](http://www.ncbi.nlm.nih.gov/pubmed?term=Burnham%20EL%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Moss M](http://www.ncbi.nlm.nih.gov/pubmed?term=Moss%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22599357), [Kern JA](http://www.ncbi.nlm.nih.gov/pubmed?term=Kern%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=22599357). BAL neuregulin-1 is elevated in acute lung injury and correlates with inflammation. [*Eur Respir J*](http://www.ncbi.nlm.nih.gov/pubmed/22599357) 41:396-401, 2013. PMID 22599357.
197. [Cole TS](http://www.ncbi.nlm.nih.gov/pubmed?term=Cole%20TS%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Zhang M](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhang%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Standiford TJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Standiford%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Newstead M](http://www.ncbi.nlm.nih.gov/pubmed?term=Newstead%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Luther J](http://www.ncbi.nlm.nih.gov/pubmed?term=Luther%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Zhang J](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Chen CC](http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=22472665), [Kao JY](http://www.ncbi.nlm.nih.gov/pubmed?term=Kao%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=22472665). IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. [*Immunol Lett.*](http://www.ncbi.nlm.nih.gov/pubmed/22472665)144:49-59, 2012. PMC3577058
198. Sun Y, Wilkinson BJ, Standiford TJ, Akinbi HT, O'Riordan MX. Fatty acids regulate stress resistance and virulence factor production for listeria monocytogenes. *J Bacteriol* 194:5274-84, 2012. PMC3457240
199. Burnham EL; Hyzy RC, Coley C; Kelly AM; Quint LE, Janssen WJ, Moss M, Standiford TJ. Chest high resolution CT features are associated with physical impairment in ALI survivors. *Critical Care Medicine* 41:445-56, 2013. PMID 23263616
200. Krupa A, Fudala R, Tucker T, Allen TC, Standiford TJ, Luchowski R, Gryczynski Z, Gryczynski I, Kurdowska A. Bruton’s tyrosine kinase mediates cross-talk between FcRlla and TLR4 signalling cascades in human neutrophils. *Am J Respir Cell Mol Biol* 48:240-9, 2013. PMID 23239500
201. Bhan I, Newstead MJ, Xianying Z, Podsaid A, Ballinger MN, Kunkel SL, Standiford TJ. TLR9-dependent IL-23/IL-17 is required for the generation of Stachybotrys chartarum-induced hypersensitivity pneumonitis.  *J Immunol* 1:190, 349-56. PMID 23180821

### **Non-Peer Reviewed Publications:**

1. Standiford TJ, Standiford CJ, Toews GB. Antibiotic therapy in patients with chronic obstructive pulmonary disease. *Int Med* 13:30-38, 1992.
2. Lynch JP III, Standiford TJ. What are your best tools for diagnosing and managing IPF. *Int Med* 14:19-38, 1993.
3. VanOtteren GM, Standiford TJ. Anticytokine Strategies in the treatment of sepsis syndrome. *Infect Med* 12:543-549, 1995.
4. Lukacs NW, Strieter RM, Standiford TJ, Kunkel SL. Characterization of chemokine function in animal models of diseases. *Methods* 10:158-165, 1996.
5. Standiford, TJ. Cytokines and pulmonary host defenses. *Cur Opin Pulm Med* 3:81-88, 1997.
6. Moore TA, Standiford TJ. The role of cytokines in bacterial pneumonia: An inflammatory balancing act. *Proceed Assoc Am Phys* 110:297-305, 1998.
7. Mehrad B, Standiford TJ. Use of animal models in the study of inflammatory mediators of pneumonia. *ILAR Journal* 40:167-174, 1999.
8. Standiford T: Anti-inflammatory cytokines and cytokine antagonists. *Curr Pharm Des* 6:633-649, 2000.
9. Moore TA, Standiford, TJ. Cytokine immunotherapy during bacterial pneumonia: from bench to bedside. *Sem Respir Infect* 16:27-37, 2001.
10. Reddy, RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. *Immunol Res* 24:273-87, 2001.
11. Reddy, RC, Standiford TJ. Immunosuppression in sepsis. *Rec Res Dev Immunol* 4:181-195, 2002.
12. Standiford TJ, Deng JC. Immunomodulation for the prevention and treatment of lung infections. *Sem Resp Crit Care Med* 25:95-108, 2004.
13. Tsai WC, Standiford TJ. Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. *Curr Pharm Design* 10:3081-93, 2004.
14. Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects macrolides on bacterial virulence: potential role as qurorum-sensing inhibitors. *Curr Pharm Design* 10:3055-65, 2004.
15. Deng JC, Standiford TJ. The systemic response to lung infection. *Clin Chest Med* 26:1-10, 2005.
16. Standiford TJ, Roman J. PPARs in lung biology and disease. *PPAR Res*. 28765: 2007. PMCID: PMC2233764
17. Lyn-Kew K, Standiford TJ. Immunosuppression of sepsis. *Curr Pharm Design* 14:1870-81, 2008. PMID: 18691098
18. Standiford TJ, Moss M. Editorial: Sepsis: evolving concepts and therapeutic strategies. *Curr Pharm Des*. 14:1832, 2008. PMID: 18691093
19. Moss M, Standiford TJ. Leptin in Fibroproliferative ALI: Not just a Satiety Factor. *Am J Respir Crit Care Med.* 183:1443-1444, 2011. PMCID: PMC3137138
20. Kovach M, Standiford TJ. Toll-like receptors in lung disease. *Int Immunopharmacol* 11:1399-406, 2011. PMID: 21624505 [PubMed - in process]
21. Kovach M, Standiford TJ. The function of neutrophils in sepsis. *Curr Opin Infect Dis* 3:321-7, 2012. PMID:22421753
22. Tolle LB, Standiford TJ. Danger-associated molecular patters (DAMPs) in acute lung injury. J Pathol 229:145-56, 2013. PMID 23097158..

**Articles Accepted for Publication**

Peer-Reviewed:

1. Yu F, Gao, N, Chen J, Standiford T, Liu X. Genome-wide transcriptional analysis of differentially expressed genes in flagellin pretreated mouse corneal epithelial cells in response to Pseudomonas aeruginosa: involvement of S100A8/A9. *Mucosal Immunology*
2. Racz J, Mane G, Ford M, Schmidt L, Myers J, Standiford T, Schumacher KR, Fifer C, Russell MW, Finkel M, Stringer KA. Immunophenotyping and protein profilling of fontan-assciated plastic bronchitis airway casts. *Proc Am Thorac Soc* *(in press).*

Non-Peer Reviewed:

1. Ballinger MN, Standiford TJ. Innate immune responses in ventilator associated pneumonia. (in press).

**Articles Submitted for Publication**

### Peer-Reviewed:

* 1. Clark BJ, Coatney J, Standiford TJ, Hyzy RC, Moss M, Burnham EL. Hospital and long-term outcomes in acute lung injury patients with unhealthy alcohol use. (submitted)
	2. Yoon G, Gao N, Kumar A, Standiford TJ, Yu F. Interferon regulatory factor-1 (IRAF1) and its role in flagellin-induced programming: differential effects on CXCL10 expression and production. (submitted)
	3. Gao N, Yoon GS, Liu X, Mi X, Standiford TJ, Yu FS X. Genome-wide transcriptional analysis of flagellin induced reprogramming in mouse corneal epithelial cells in response to *Pseudomonas aeruginosa*: involvement of S100A8/A9.
	4. Bosmann M, Grailer JJ, Russkamp NF, Ruemmler R, Moore B, Monestier M, Zetoune F, Sarma JV, Standiford T, Ward PA. Extracellular histones promote complement-induced acute lung injury. (submitted)
1. Liu X, Gao N, Yoon G, Standiford TJ, Yu F. Epithelium-expressed CXCL10 and natural killer cells in protective corneal mucosal immunity against *Candida albicans* infection (submitted)
2. Kovach MA, Bunting RA, Wu X, San Mateo L, Newstead MW, Paine R, Standiford TJ. Identification of unique alveolar macrophage molecular phenotypes in patients with acute lung injury using microarray analysis (*submitted*).

Non-Peer Reviewed:

None

**Chapters in Books**

1. Kunkel SL, Strieter RM, Chensue SW, Basha M, Standiford T, Ham J, Remick DG. Tumor necrosis factor-α, interleukin-8, and chemotactic cytokines. In: Melli M and Parente L (eds.). *Cytokines and Lipocortins in Inflammation and Differentiation*. Wiley-Liss, Inc., New York, pp. 433-444, 1990.
2. Abruzzo LV, Strieter RM, Standiford TJ, Kunkel SL. MIP-1 gene expression *in vivo* and *in vitro*. In: Oppenheim JJ, Pawanda MC, Kluger MJ, and Dinarello CA (eds.). *Molecular and Cellular Biology of Cytokines*. Wiley-Liss, Inc., New York, pp. 403-408, 1990.
3. Kunkel SL, Standiford TJ, Strieter RM. Cytokine-Dependent Interleukin-8 Expression and its Role in Cell Communication. In: Redl H. and Schlag G. (eds.). Second Wiggers-Bernard Conference on *Shock*, *Sepsis and Organ Failure*. Springer-Verlag, Heidelberg, Germany, 1990.
4. Kunkel SL, Standiford T, Kasahara K, Strieter RM. Stimulus specific induction of monocyte chemotactic protein-1 (MCP-1) gene expression. In: Kunkel SL, Lindley I, and Warwick J (eds.). *Chemotactic Cytokines*. Karger, 1990.
5. Strieter RM, Standiford T, Chensue SW, Kasahara K, Kunkel SL. Induction and regulation of interleukin-8 gene expression. In: Kunkel SL, Lindley I, and Warwick J (eds.). *Chemotactic Cytokines*. Karger, 1990.
6. Kunkel SL, Standiford T, Westwick J, Chensue SW, Strieter RM. Interleukin-8 and the inflammatory response. In: Kunkel SL, and Remick DG (eds.). *Cytokines in Health and Disease: Physiology and Pathophysiology.*  Marcel Dekker, Inc., New York, 1991.
7. Strieter RM, Standiford TJ, Rolfe MW, Lynch III JP, Metinko AP, Kunkel SL. Cytokines in Pulmonary Injury. In: Kunkel SL, and Remick DG (eds.). *Cytokines in Health and Disease: Physiology and Pathophysiology.* Marcel Dekker, Inc., New York, 1991.
8. Kunkel SL, Standiford T, Metinko AP, Strieter RM. Endothelial cell-derived novel chemotactic cytokines. In: Lenfant C (ed.). Lung Vascular Injury: *Molecular and Cellular Response.* Marcel Dekker, Inc., New York, 1991.
9. Kunkel SL, Chensue SW, Standiford TJ, Strieter RM. Cellular and molecular mechanisms that regulate the production of interleukin-8: The potential role of chemotactic cytokines in ARDS and multiple organ failure. In: Faist E (ed.). International Congress on the Immune Consequences of Trauma, *Shock and Sepsis - Mechanism and Therapeutic Approaches*. Springer-Verlag, Heidelberg, Germany, 1991.
10. Kunkel SL, Standiford TJ, Chensue SW, Kasahara K, Strieter RM. Cellular and molecular mechanisms of cytokine networking. In: Parnham MJ, Bray MA, van den Berg WB (eds.). *Agents and Actions Supplements - Vol. 32 Drugs in Inflammation, Cellular and Molecular Mechanisms of Cytokine Networking.* Birkhauser Verlag, Boston, MA, pp. 205-218, 1991.
11. Strieter RM, Standiford TJ, Rolfe MW, Kunkel SL. Interleukin-8. In: Kelley J. (ed.). *Cytokines of the Lung: Lung Biology in Health and Disease.*  Marcel Dekker, Inc., New York, 1991.
12. Kunkel SL, Standiford T, Kasahara K, Strieter RM. Stimulus specific induction of monocyte chemotactic protein-1 (MCP-1) gene expression. In: Kunkel SL, Lindley I, and Warwick J (eds.). *Chemotactic Cytokines.*  Karger, pp. 65-72, 1991.
13. Kunkel SL, Standiford TJ, Rolfe MW, Strieter RM. Expression and regulation of chemotactic cytokine genes by non-immune pulmonary cells. In: Brody A, Center D, Tkachuk V (eds.). *Signal Transduction in Lung Cells: Lung Biology in Health and Disease*. Marcel Dekker, Inc., New York, 1992.
14. Kunkel SL, Standiford TJ, Rolfe MW, Strieter RM. The role of chemotactic cytokines in diverse pathophysiologic diseases. In: Mantovani A, Ghezzi P (eds.). *Pathophysiology and Pharmacology of Cytokines.* Biomedical Press, New York, 1992.
15. Strieter RM, Colletti LM, Metinko AP, Rolfe MW, DeMeester SR, Standiford TJ, Kunkel SL. The role of cytokine networks mediating inflammation and ischemia-reperfusion injury. In: Schlag G, Redl H (ed.). *Third Wiggers Bernard Conference on Shock, Sepsis and Organ Failure*. Springer-Verlag, Heidelberg, Germany, 1992.
16. Kunkel SL, Standiford TJ, Kasama T, Strieter RM. Chemotactic Cytokines: The chemokine family. In: Phan SH, Thrall RS, (eds.). *Pulmonary Fibrosis: Lung Biology in Health and Disease.*  Marcel Dekker, Inc., New York, 1993.
17. Kunkel SL, Chensue SW, Standiford TJ, Strieter RM. Endotoxin-dependent cytokine networks. In: Brigham KL (ed). *Endotoxin and the Lung: Lung Biology in Health and Disease*. Marcel Dekker, Inc., New York, 1993.
18. Kunkel SL, Standiford TJ, Strieter RM, Kasama T. Chemotactic Cytokines: The chemokine family. In: Phan SH, Thrall RS, (ed.). *Pulmonary Fibrosis.* Marcel Dekker, Inc., New York, pp. 579-597, 1994.
19. Huffnagle GB, Strieter RM, Kunkel SL, Toews GB, Standiford TJ. The role of chemokines in pneumonia. In: Koch A, Strieter RM, (ed.). *Chemokines in Disease* Biomedical Publishers, Austin, TX, 1995.
20. Strieter RM, Standiford TJ, Colletti LM, Kunkel SL. The role of chemokines in disease. In: Koch AE, Strieter RM, (eds.) *Neutrophil recruitment in acute lung injury: The interplay of early response cytokines, adhesion molecules, and CXC chemokines.* Biomedical Publishers, Austin, TX, 1995.
21. Strieter RM, Standiford TJ, Colletti LM, Kunkel SL. Neutrophil recruitment in acute lung injury: the interplay of early response cytokines, adhesion molecules, and C-X-C chemokines. In: Koch A, Strieter RM, (ed.) *Chemokines in Disease* Biomedical Publishers, Austin, TX, 1995.
22. Kunkel SL, Standiford TJ, Caldwell C, Lukacs N, Strieter RM. Cytokine-induced mechanisms of acute lung injury leading to ARDS. In: Russell and Walley (eds.) ARDS: a comprehensive clinical approach. Cambridge University Press, London, UK, 1996.
23. Standiford TJ, Kunkel SL, Strieter RM. Methods for assessing the role of chemokines in lung antibacterial host defense. In: Horuk R (ed.) *Chemokines and chemokine receptors (a volume of methods in enzymology)* Academic Press, San Diego, CA, 1997.
24. Kunkel SL, Lukacs N, Strieter RM. Cytokines networks dictate inflammatory events at the alveolar interface. In: Vincent J (ed.) *Update in Intensive Care and Emergency Medicine* Springer-Verlag, Berlin, Germany, 1997.
25. Kunkel SL, Lukacs N, Hogaboam C, Strieter RM, Standiford TJ. Advanced forms of pharmacological intervention on pulmonary host defenses. In: Vincent J. (ed.) *Update in Intensive Care and Emergency Medicine.* Springer-Verlag, Berlin, Germany, 1997.
26. Strieter RM, Keane MP, Standiford TJ, Kunkel SL. Cytokine Biology and the pathogenesis of interstitial lung disease. In: Schwarz MI, King TE (eds.) *Interstitial Lung Disease*. B.C. Decker, Inc., Hamilton, Ontario, Canada, 1998, pp.181-205.
27. Peters-Golden M, Standiford TJ. Antimicrobial defense capabilities of the lung. In: P Smith, P Warne (eds.) *Emerging Therapeutic Targets.* Ashley Publications, London, UK, 1998, 2(1):15-18.
28. Kunkel SL, Chensue SW, Colletti L, Standiford TJ, Lukacs N, Strieter RM. Cytokine networks dictate leukocyte recruitment. In: Nelson S, Martin T. (eds.) *Pathogenesis and Therapeutic Strategies*. Marcel-Dekker, New York, NY, 2000.
29. Kolls J, Standiford TJ. Novel approaches in the treatment of bacterial infection. In: Nelson S, Martin T. (eds.) Pathogenesis *and Therapeutic Strategies*. Marcel-Dekker, New York, NY, 2000.
30. Standiford TJ, Mehrad B, Tsai WC, Moore TA. Cytokines as mediators of lung innate immunity. In: Vincent J. (ed.) *Update in Intensive Care and Emergency Medicine*. Springer-Verlag, Berlin, Germany, 2000.
31. Lira SA, Vallileva G, Chen SC, Lukacs NW, Chensue SW, Standiford TJ, Mehrad B, Cook DN. Genetic models to study chemokine biology in the lung. In: Streiter RM, Kunkel SL, Standiford TJ (eds.) Chemokines *in the Lung*. Marcel Dekker, New York, NY, Vol. 172:65-80, 2003.
32. Standiford TJ, Mehrad B. Chemokines in infectious diseases of the lung. In: Streiter RM, Kunkel SL, Standiford TJ (eds.) Chemokines *in the Lung*. Marcel Dekker, New York, NY, Vol. 172:145-70, 2003.
33. White ES, Standiford TJ. The role of polymorphonuclear leukocytes in the pathogenesis of idiopathic pulmonary fibrosis. In: Lynch J (ed) *Idiopathic Pulmonary Fibrosis.* Lung Biology in Health and Disease Series (Lenfant (exec. ed.),Marcel Dekker, New York, NY, Vol. 185:341-57, 2004.
34. Standiford TJ, Deng JC. Interleukins: IL-10. In Laurent GJ, Shapiro SD (eds.). *Encyclopedia of Respiratory Medicine*, Elsevier Ltd., Kidlington, Oxford, UK, Vol. 1:373-76, 2006.
35. Karaolis DKR, Standiford TJ. Cyclic di-GMP Signaling and Host Immunity. Chapter 21. In: The Second Messenger Cyclic Di-GMP. ASM Press. A.J. Wolfe and K.L. Visick eds. 304-310, 2009.
36. Standiford TJ, Deng JC. Growth factors and cytokines in acute lung injury. In Gillespie M, Stevens T, Wagner W, (eds.) American Physiological Society Handbook: Compr Physiol 1:81-104, 2011.
37. Ballinger MN, Standiford TJ. Innate immune responses in ventilator associated pneumonia. In: Prince A (ed). Mucosal immunology of acute bacterial infection. Springer, New York, NY, .Vol 1:185-212, 2013.
38. Standiford TJ, Toews GB, Huffnagle GB. Pulmonary Clearance of Infectious Agents. In Fishman (ed). Pulmonary Diseases and Disorders, Fifth edition .

**Books/Journals Edited**

1. Strieter RM, Kunkel SL, Standiford TJ (eds.) *Chemokines in the Lung*. Marcel Dekker, New York, NY, Vol. 172, 2003.
2. Standiford TJ, Nelson S. (eds.) Pulmonary Defense Mechanisms in Infection. *Sem Resp Crit Care Med* Vol. 25, 2004.
3. Standiford TJ, Martinez F, (eds.) Immunomodulatory Effects of Macrolides in the Lung. *Curr Pharm Design* Vol. 10, 2004.
4. Standiford TJ, Roman J, (eds) PPARs/ RXRs in Lung Health and Disease, *PPAR Research*. Vol 4, 2007.
5. Standiford TJ, Moss, M, (eds) Sepsis: Evolving Concepts and Therapeutic Strategies, *Curr Pharm Design* Vol. 14, 2008.

**Abstracts**

Abstracts not listed.